Epstein–Barr virus

Epstein–Barr virus
Liza Gross · CC BY 2.5 · source
Name	Epstein–Barr virus
Virus group	Herpesviridae
Family	Herpesviridae
Subfamily	Gammaherpesvirinae
Genus	Lymphocryptovirus
Species	Human gammaherpesvirus 4
Genome	Double-stranded DNA

Epstein–Barr virus is a human herpesvirus associated with infectious mononucleosis, multiple lymphoid and epithelial malignancies, and diverse autoimmune and chronic conditions. First characterized in tumoral tissue from Burkitt and Hodgkin cases, it is studied across virology, oncology, immunology, and global public health fields. Research spans clinical trials, vaccine development, molecular biology, and epidemiologic surveillance by institutions and consortia.

Taxonomy and Virology

Epstein–Barr virus belongs to the family Herpesviridae and subfamily Gammaherpesvirinae, related to Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 within the genus Lymphocryptovirus; taxonomic classification is maintained by the International Committee on Taxonomy of Viruses, World Health Organization, and Centers for Disease Control and Prevention. The viral particle comprises an icosahedral capsid, tegument, and lipid envelope bearing glycoproteins homologous to those characterized in Varicella‑zoster virus, Cytomegalovirus, and Herpes simplex viruses; sequencing efforts led by teams from the Wellcome Trust Sanger Institute, Broad Institute, and National Institutes of Health clarified the ~170 kb double‑stranded DNA genome and multipartite latency and lytic gene expression programs. Viral latency-associated proteins (including EBNA family and LMP proteins) and noncoding RNAs such as EBERs were defined in laboratory models including Burkitt lymphoma cell lines, Hodgkin Reed–Sternberg studies, and xenografts used by investigators at Harvard Medical School, Johns Hopkins University, and Cold Spring Harbor Laboratory.

Epidemiology and Transmission

Infection is ubiquitous worldwide with seroprevalence patterns described by WHO, UNICEF, and national public health agencies: higher childhood acquisition in sub-Saharan Africa, South Asia, and Latin America versus adolescent and young adult primary infection in North America, Western Europe, and East Asia as documented by cohort studies from the Framingham Heart Study, CDC surveillance, and University of Oxford research. Transmission occurs primarily via saliva through intimate contact, as investigated in household transmission studies, school outbreak reports, and hospital infection control investigations by NHS trusts and Médecins Sans Frontières; transfusion, transplantation, and perinatal transmission are described in case series reported by American Red Cross, Eurotransplant, and transplant centers at Mayo Clinic and Cleveland Clinic. Epidemics and serologic surveys linking EBV to endemic Burkitt lymphoma and nasopharyngeal carcinoma have been highlighted in epidemiologic work from Uganda Cancer Institute, IARC, and Guangdong provincial registries.

Clinical Manifestations and Complications

Primary symptomatic infection often presents as infectious mononucleosis with fever, pharyngitis, lymphadenopathy, and splenomegaly, features detailed in case reports from Johns Hopkins Hospital, St. Mary’s Hospital, and Royal Free Hospital. EBV is etiologically linked to malignancies including endemic Burkitt lymphoma, Hodgkin lymphoma, post‑transplant lymphoproliferative disorder (PTLD), and nasopharyngeal carcinoma in datasets from Uganda Cancer Institute, Memorial Sloan Kettering, and Sun Yat‑sen University Cancer Center; associations with gastric carcinoma and smooth muscle tumors in immunocompromised hosts have been documented by oncologists at MD Anderson Cancer Center and Karolinska Institutet. Chronic active EBV disease, hemophagocytic lymphohistiocytosis, and autoimmune associations reported in clinical series by Cleveland Clinic, University of Tokyo, and NIH underscore multisystem involvement.

Pathogenesis and Immune Response

Pathogenesis integrates B‑cell tropism mediated by CD21 and HLA class II interactions, epithelial cell infection, and latency programs that modulate apoptosis, proliferation, and immune evasion—mechanisms dissected by laboratories at Rockefeller University, University of Cambridge, and Institut Pasteur. Host responses involve innate sensing pathways including toll‑like receptors characterized in studies from University of California, San Francisco, adaptive cytotoxic T lymphocyte responses mapped by investigators at Scripps Research Institute and Memorial Sloan Kettering, and immune modulation relevant to vaccine strategies pursued by GSK, Moderna, and NIH Vaccine Research Center. Co‑factors such as malaria, HIV, and environmental carcinogens in studies from Makerere University, University of Nairobi, and Peking University modify progression to malignancy.

Diagnosis and Laboratory Testing

Diagnostic approaches rely on serology (heterophile antibody tests and EBV‑specific IgM/IgG against viral capsid antigen and nuclear antigen), nucleic acid amplification by PCR, and in situ hybridization for EBERs used in pathology labs at Mayo Clinic, Cleveland Clinic, and University College London Hospitals. Flow cytometry, immunohistochemistry for LMP1, and high‑throughput sequencing from centers such as Broad Institute, Institut Curie, and Memorial Sloan Kettering support tumor classification and minimal residual disease monitoring. Blood bank screening, transplant donor evaluation, and epidemiologic surveillance protocols have been developed by American Association of Blood Banks, EuroGentest, and WHO reference laboratories.

Prevention and Treatment

Prevention strategies include hygiene education in schools, screening protocols for transfusion and transplantation endorsed by Red Cross, NHS Blood and Transplant, and policy groups at CDC; vaccine development efforts have been led by academic‑industry partnerships involving GSK, Moderna, NIH, and University of Oxford employing recombinant gp350, vectored, and mRNA platforms. Antiviral therapy using acyclovir and ganciclovir shows activity against lytic replication in trials reported by Cochrane Reviews and clinical centers, while management of complications uses corticosteroids, rituximab, chemotherapy regimens from EORTC protocols, and hematopoietic stem cell transplantation practiced at Fred Hutchinson Cancer Research Center and Johns Hopkins. Post‑transplant immunosuppression modulation and adoptive T‑cell therapies are offered in specialized centers including University of Pennsylvania and Baylor College of Medicine.

History and Public Health Impact

The virus was identified by Anthony Epstein and Yvonne Barr in collaboration with Denis Burkitt in the 1960s amid research at the Uganda Cancer Institute and published through institutions including the Royal College of Surgeons and University of Bristol; subsequent work by researchers at Columbia University, Stanford University, and Rockefeller University expanded links to lymphomas and nasopharyngeal carcinoma. Its global burden informs cancer control programs at IARC, WHO, and national cancer registries, shaping screening, research funding from NIH, Wellcome Trust, and European Commission, and informing public health responses by CDC, Public Health England, and national ministries of health.

Category:Human viruses